首页> 美国卫生研究院文献>BJR Open >Evaluation of diffusion-weighted MRI and (18F) fluorothymidine-PET biomarkers for early response assessment in patients with operable non-small cell lung cancer treated with neoadjuvant chemotherapy

【2h】

Evaluation of diffusion-weighted MRI and (18F) fluorothymidine-PET biomarkers for early response assessment in patients with operable non-small cell lung cancer treated with neoadjuvant chemotherapy

机译：用新辅助化疗治疗可操作的非小细胞肺癌患者早期反应评估的扩散加权MRI和（18F）氟胞嘧啶-PET生物标志物

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

To correlate changes in the apparent diffusion coefficient (ADC) from diffusion-weighted (DW)-MRI and standardised uptake value (SUV) from fluorothymidine (18FLT)-PET/CT with histopathological estimates of response in patients with non-small cell lung cancer (NSCLC) treated with neoadjuvant chemotherapy and track longitudinal changes in these biomarkers in a multicentre, multivendor setting.

机译：将表观扩散系数（ADC）与来自氟胞嘧啶（18FLT）-PET / CT的显着扩散系数（ADC）的变化与非小细胞肺癌患者的响应组织病理学估计相关（NSCLC）用Neoadjuvant化疗治疗，并在多中心的多中心设置中追踪这些生物标志物的纵向变化。

著录项

期刊名称 BJR Open
作者
Dominic Carlin; Alexander Weller; Gem Kramer; Yan Liu; John C Waterton; Arturo Chiti; Martina Sollini; A Joop de Langen; Mary E R O’Brien; Maria Urbanowicz; Bart KM Jacobs; Nandita deSouza;
展开▼
作者单位

展开▼
年(卷),期 2019(1),1
年度 2019
页码 20190029
总页数 12
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. [J] . Eschmann SM, Friedel G, Paulsen F, European Journal of Nuclear Medicine and Molecular Imaging . 2007,第4期

机译：18F-FDG PET用于评估III期非小细胞肺癌新辅助放化疗后的治疗反应和术前重新评估。
2. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer [J] . Susanne Martina Eschmann, Godehard Friedel, Frank Paulsen, European Journal of Nuclear Medicine and Molecular Imaging . 2007,第4期

机译：18 F-FDG PET评估III期非小细胞肺癌新辅助放化疗后的治疗反应和术前重新评估
3. P2.01-113 Prognostic Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients with Operable Stage III-N2 Non-Small Cell Lung Cancer (NSCLC) [J] . L. Yong, S. Kuo, P. Yang, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：n2.01-113 Neoadjuvant和辅助化疗治疗可操作阶段III-N2非小细胞肺癌（NSCLC）患者的预后作用
4. Radiomics Biomarkers from PET/CT Multi-modality Fusion Images for the Prediction of Immunotherapy Response in Advanced Non-small Cell Lung Cancer Patients [C] . Wei Mu, Jin Qi, Hong Lu, SPIE Medical Imaging Conference . 2018

机译：PET / CT多模态融合图像的放射性标记生物标志物用于预测晚期非小细胞肺癌患者的免疫治疗反应
5. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
6. 18F-fluorothymidine (FLT)-PET and diffusion-weighted MRI for early response evaluation in patients with small cell lung cancer: a pilot study [O] . Tine Nøhr Christensen, Seppo W. Langer, Katrine Engholm Villumsen, 2020

机译：小细胞肺癌患者的早期反应评估18F-氟胞嘧啶（FLT） - 氟和扩散加权MRI：试验研究
7. Predictive value of integrated18F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer [O] . Yukihiro Umeda, Miwa Morikawa, Masaki Anzai, 2020

机译：综合18F-FDG PET / MRI在患有先前治疗的非小细胞肺癌患者患者的早期反应中的预测值

Evaluation of diffusion-weighted MRI and (18F) fluorothymidine-PET biomarkers for early response assessment in patients with operable non-small cell lung cancer treated with neoadjuvant chemotherapy

摘要

著录项

相似文献

相关主题

期刊订阅